Watch ACRS. Know when insiders buy.
One email the day a filing lands. Free.
ACRS
Aclaris Therapeutics, Inc.
6.17
+0.22 +3.70%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
34
FLAG · shorts 34
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $908.2MP/E —DIV YIELD —FCF YIELD -6.85%REV TTM $8.2M −51.0%NET INCOME −$75.7MNET CASH $8.4M52W 1.81 – 6.53SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.6M | −8.3% | 86.6% | −$24.2M | −$21.5M | — | -0.15 | −$19.8M | $58K | −$19.9M | Aug 6 |
| Q1 2026 · Mar 31 | $2M | +37.2% | 80.2% | −$22.2M | −$19.8M | — | -0.15 | −$18.1M | $13K | −$18.2M | Aug 6 |
| Q4 2025 · Dec 31derived | $1.3M | −85.9% | 58.9% | −$22.7M | −$19.8M | — | -0.16 | −$13.1M | $24K | −$13.2M | Feb 26 |
| Q3 2025 · Sep 30 | $3.3M | −24.1% | 83.7% | −$17.1M | −$14.6M | — | -0.12 | −$10.9M | $23K | −$11M | Nov 6 |
| Q2 2025 · Jun 30 | $1.8M | −35.8% | 71.0% | −$18.4M | −$15.4M | — | -0.13 | −$10M | $21K | −$10M | Aug 6 |
| Q1 2025 · Mar 31 | $1.5M | −39.3% | 65.2% | −$18.1M | −$15.1M | — | -0.12 | −$13.1M | $43K | −$13.1M | Aug 6 |
| Q4 2024 · Dec 31derived | $9.2M | −47.6% | 92.3% | −$99.7M | −$96.6M | — | -1.21 | −$8.9M | $0 | −$8.9M | Feb 26 |
| Q3 2024 · Sep 30 | $4.3M | −53.2% | 85.0% | −$10.5M | −$7.6M | — | -0.11 | $22M | $0 | $22M | Nov 6 |
| Q2 2024 · Jun 30 | $2.8M | — | 77.4% | −$12.9M | −$11M | — | -0.15 | −$12.3M | −$14K | −$12.3M | Nov 6 |
| Q1 2024 · Mar 31 | $2.4M | — | 66.3% | −$18.9M | −$16.9M | — | -0.24 | −$20.8M | $135K | −$20.9M | Nov 6 |
| Q4 2023 · Dec 31derived | $17.6M | — | 95.9% | −$4M | −$1.5M | — | -0.02 | −$6.8M | $441K | −$7.2M | Feb 27 |
| Q3 2023 · Sep 30 | $9.3M | — | 90.9% | −$31.6M | −$29.3M | — | -0.41 | −$24.6M | $84K | −$24.6M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.8M | 73.3% | −$76.4M | −$64.9M | -829.6% | -0.53 | −$47.1M | $111K | −$47.2M | — | — |
| FY2024 · to Dec 31 | $18.7M | 85.1% | −$141.9M | −$132.1M | -705.5% | -1.71 | −$20.1M | $121K | −$20.2M | — | — |
| FY2023 · to Dec 31 | $31.2M | 89.0% | −$97.4M | −$88.5M | -283.1% | -1.27 | −$78.3M | $1.3M | −$79.6M | — | — |
| FY2022 · to Dec 31 | $29.8M | 86.5% | −$89.9M | −$86.9M | -292.1% | -1.33 | −$67.6M | $605K | −$68.2M | — | — |
| FY2021 · to Dec 31 | $6.8M | 30.3% | −$89.7M | −$90.9M | -1344.0% | -1.60 | −$52.1M | $308K | −$52.4M | — | — |
| FY2020 · to Dec 31 | $6.5M | 20.8% | −$50.9M | −$51M | -787.0% | -1.20 | −$38.6M | $453K | −$39.1M | — | — |
Every number comes from Aclaris Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.